| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/21/2003 | US6509177 Cultivating on a medium comprising at least one organic nitrogen or carbon source, in submerged aerated conditions, a Pseudomonas bacterium strain capable of the biosynthesis of pseudomonic acid A |
| 01/21/2003 | US6509162 Methods for selectively modulating survivin apoptosis pathways |
| 01/21/2003 | US6509155 Characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly colon cancer |
| 01/21/2003 | US6509154 Product comprising at least a double stranded RNA combined with at least an antiviral agent |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509014 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema |
| 01/21/2003 | US6509005 Nonozone depleting stable aerosol; treating nausea and vomiting associated with chemotherapy; muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma and mood disorders |
| 01/21/2003 | US6509002 Carbon 13 labeled lactic acid and carrier for parenteral or oral administration; measuring radioactivity level of exhaled carbon monoxide; accurate even in light cases where subject exhibits normal blood sugar levels at time of fasting |
| 01/21/2003 | CA2204253C Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
| 01/21/2003 | CA2078106C Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/20/2003 | CA2416600A1 Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | WO2002006214A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415954A1 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/17/2003 | CA2407295A1 Transgenic non-human mammal |
| 01/16/2003 | WO2003005038A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 01/16/2003 | WO2003004702A2 Method for determining chromatin structure |
| 01/16/2003 | WO2003004628A2 Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004607A2 Aggrecanase molecules |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004509A2 C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004501A2 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004496A1 Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| 01/16/2003 | WO2003004495A1 Novel immunomodulating compounds |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004488A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004485A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof |
| 01/16/2003 | WO2003004484A1 Novel aliphatic compounds, synthesis method and method of using the same |
| 01/16/2003 | WO2003004480A2 Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| 01/16/2003 | WO2003004479A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | WO2003004478A1 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) |
| 01/16/2003 | WO2003004475A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004473A1 Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| 01/16/2003 | WO2003004472A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004468A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004466A2 Dye-sulfenates for dual phototherapy |
| 01/16/2003 | WO2003004098A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | WO2003004097A1 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
| 01/16/2003 | WO2003004066A1 Gene therapeutics |
| 01/16/2003 | WO2003004065A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 01/16/2003 | WO2003004047A1 Cell death inducers for mast cells |
| 01/16/2003 | WO2003004042A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 01/16/2003 | WO2003004034A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 01/16/2003 | WO2003004028A1 Tetrahydroquinoline derivatives |
| 01/16/2003 | WO2003004027A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | WO2003004018A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 01/16/2003 | WO2003004017A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones |
| 01/16/2003 | WO2003004007A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | WO2003004006A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | WO2003004004A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 01/16/2003 | WO2003003986A2 Parathyroid hormone antibodies and related methods |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003972A2 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 01/16/2003 | WO2003003941A2 One dose vaccination with mycoplasma hyopneumoniae |
| 01/16/2003 | WO2003003833A1 Antiviral composition and treatment method |
| 01/16/2003 | WO2003003824A1 Potential-dependent ca2+ channel a1b knockout non-human animal |
| 01/16/2003 | WO2003003806A2 Dye-azide compounds for dual phototherapy |
| 01/16/2003 | WO2002096394A3 Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl |
| 01/16/2003 | WO2002085857A3 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 01/16/2003 | WO2002085387A3 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
| 01/16/2003 | WO2002085386A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/16/2003 | WO2002085385A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002076930A3 Substituted diarylureas as stimulators for fas-mediated apoptosis |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 01/16/2003 | WO2002051837A3 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 01/16/2003 | WO2002050034A3 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 01/16/2003 | WO2002042445A3 Differentiated cells suitable for human therapy |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002038176A3 Immunogenic compositions comprising liver stage malarial antigens |
| 01/16/2003 | WO2002036107A3 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 01/16/2003 | WO2002034247A3 Anticancer agents based on regulation of protein prenylation |
| 01/16/2003 | WO2002022171A3 Pharmaceutical composition having specific water activity |
| 01/16/2003 | WO2002016587A3 Microtubule-associated proteins and tubulins |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2002010406A3 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 01/16/2003 | WO2002005818A3 Novel method of use of multidrug resistance modulators |
| 01/16/2003 | WO2002004021A9 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/16/2003 | WO2001092490A3 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 01/16/2003 | WO2001091739A3 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 01/16/2003 | WO2001090192A3 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001087937A3 G-protein coupled receptors |
| 01/16/2003 | WO2001085941A9 Myc targets |
| 01/16/2003 | WO2001070174A8 Vegf-modulated genes and methods employing them |
| 01/16/2003 | WO2001062705A3 Aminoalcohol derivatives |
| 01/16/2003 | WO2001060315A3 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 01/16/2003 | WO2001058954A9 Trade molecules and uses related thereto |
| 01/16/2003 | US20030013886 Such as (E)-1-(2-Pyridyl)-2-styryl-1H-benzimidazole; antiinflammatory and analgesic agents; prostaglandin inhibitors |
| 01/16/2003 | US20030013861 E-isomeric fullerene derivatives |